Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188189 | 0.92 | PARP1 (0.50) | PARP1PARP2 | |
| SCHEMBL4192763 | 0.91 | PARP1 (0.52) | PARP1PARP2 | |
| SCHEMBL4198252 | 0.91 | PARP1 (0.53) | PARP1PARP2 | |
| SCHEMBL4190638 | 0.86 | PARP1 (0.50) | PARP1PARP2 | |
| SCHEMBL4197636 | 0.85 | PARP1 (0.62) | PARP1PARP2 | |
| SCHEMBL4188122 | 0.85 | AURKB (0.52) | PARP1PARP2 | |
| SCHEMBL4191029 | 0.84 | PARP1 (0.57) | PARP1PARP2 | |
| SCHEMBL4195514 | 0.84 | PARP1 (0.55) | PARP1PARP2 | |
| SCHEMBL4198237 | 0.84 | PARP1 (0.51) | PARP1PARP2 | |
| SCHEMBL4183655 | 0.83 | PARP1 (0.57) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | claimed |
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP11, PARP2 | PARP1 1/4885PARP2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.